| Bioactivity | Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum[1]. | ||||||
| In Vivo | Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibite intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7[1]. Animal Model: | ||||||
| Name | Apraglutide | ||||||
| CAS | 1295353-98-8 | ||||||
| Shortening | HGDGSFSDEX FTILDLLAAR DFINWLIQTK ITD-NH2 | ||||||
| Formula | C172H263N43O52 | ||||||
| Molar Mass | 3765.25 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||
| Reference | [1]. Slim GM, et al. Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. JPEN J Parenter Enteral Nutr. 2019 Jan 6. |
Apraglutide
CAS: 1295353-98-8 F: C172H263N43O52 W: 3765.25
Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and lin
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.